Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
about
Teicoplanin metabolism in humansNanomechanics of drug-target interactions and antibacterial resistance detectionPharmacokinetics of vancomycin in adult cystic fibrosis patients.Application of a Bayesian method to monitor and adjust vancomycin dosage regimensPharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteersEffect of cardiopulmonary bypass on vancomycin and netilmicin dispositionVancomycin pharmacokinetics in patients with various degrees of renal function.Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteersVancomycin entry into lung lymph in sheep.Protein binding of vancomycin in a patient with immunoglobulin A myeloma.Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalizationConcentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitisPharmacokinetics of vancomycin in patients with various degrees of renal function.Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.The pharmacokinetic and pharmacodynamic properties of vancomycin.The 6R's of drug induced nephrotoxicitySurface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients.Vancomycin therapeutic drug monitoring: is it necessary?Therapeutic update on glycopeptide and lipopeptide antibiotics.Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (Ziracin), in healthy subjects.Vancomycin ototoxicity and nephrotoxicity. A review.A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.Vancomycin: an update.Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.Serum protein-binding characteristics of vancomycin.Comparison of radioimmunoassay and fluorescent polarization immunoassay for quantitative determination of vancomycin concentrations in serum.Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.Population pharmacokinetic parameters of vancomycin in critically ill patients.Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.Prospective trial of a novel nomogram to achieve updated vancomycin trough concentrations.Impact of vancomycin therapeutic drug monitoring on patient care.Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.Evaluation of the Safety of a Vancomycin Nomogram Used to Achieve Target Trough Concentrations.Evaluation of three methods for determining initial vancomycin doses.Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients.Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Evaluation of a new vancomycin dosing method.
P2860
Q24671805-844CD816-DAF4-42B5-B05F-D3F66D84038CQ35032025-9F2F72C7-5D40-4DEE-A1F0-22D76601D49AQ35121949-AF53E29C-A1C9-4875-93BB-888D2FF37CAAQ35261758-49EFEFAC-78A2-4327-B1C6-EE16563CE868Q35289147-5A5E0AB0-D5DF-4099-A68D-A2434D3B066DQ35303026-402748F5-C510-4E38-9981-56474555FEEFQ35308855-9C67EF87-1E6A-463E-BD12-5D12DCFB50CAQ35537659-9699F67A-0367-49EA-9259-58EC17629EC5Q35543095-BF189112-AD10-4C12-8F7A-235228E4E271Q35565490-91AC374F-7ADC-40FA-811D-98DFBE250FF5Q35689318-41FEB435-B852-4330-96F0-B21CFF761210Q35756518-7B186DE0-9A1A-4092-8161-8D534D73D18DQ35758814-E36207AA-10F3-4F6B-A57C-503D82589F56Q35809992-BD807D6A-A0DC-48C9-8E1D-049D2EDD9514Q36328971-5CEF79B6-5B42-4C3F-A335-0D7D05273931Q36333140-C7F2BF31-D08C-4DD5-A75F-555059498F9EQ37623139-9B9F532C-D86D-4D7F-9A03-2F2972C511B7Q38258649-6B1AD6D1-A0A3-4F9F-A42D-7DC10D511D3EQ38271273-289317D6-361E-4B50-87D3-5949136C20F5Q38566835-99D953D5-4C47-41B4-ABF8-E03010A04C8FQ39291062-873D7319-DD90-4882-BAE9-0E535714A458Q39476658-F16AE9E1-1E3A-4FA6-993C-D01AC939D631Q39542494-DE0FB176-CE8D-4116-9257-4E092426C5B7Q39623184-86BFBAFA-68C2-49E4-BAC7-7A33D5502CCCQ39746652-F12F835C-C60B-41D0-AE12-A16212DCBAC3Q39834969-F99C5D8F-4329-4308-9F61-CD451B584F14Q39866031-04DDD0B1-DC9E-4FA2-882B-D31D00B9E6F2Q40217172-C3C77964-8A10-441E-88B6-05C1D307DB63Q40219056-B1D054EF-3086-4C14-B28F-46292804425EQ40290397-C49582D1-4F0D-454D-BD86-3E6E84559EF2Q41508527-F8CCC2E7-2B3C-4D57-AFE1-8D411A01C181Q41908186-F6D1B772-8560-4998-9FE7-0AA075EDB0D5Q42278351-69CF079D-6A69-49AD-B33F-76A10E8E5BEFQ42341701-43DCAF4F-D9F0-4450-8BD5-9CD0A9B29F14Q42385439-53CE3111-7D1A-438F-A203-708DBA699567Q42646255-58192E32-4395-4080-A12D-7ABD2E87F016Q42651257-98C03410-C637-4BB6-B474-95550A94F979Q43405839-5704EC86-B482-407D-B693-B403D480FB25Q43984406-3D9A9826-F8F6-431E-8F0E-A1B012FB87C1Q44843571-FE241E9A-514A-4EE0-A471-BA04FD5883A2
P2860
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@ast
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@en
type
label
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@ast
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@en
prefLabel
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@ast
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
@en
P2093
P2860
P304
P356
10.1128/AAC.22.3.391
P407
P577
1982-09-01T00:00:00Z